EUROPEAN COMMISSION

Brussels, 6.10.2021
C(2021) 7350 final

PUBLIC VERSION

Advent International Corporation
Prudential Tower
800 Boylston Street, Suite 3300
MA 02199 Boston
United States of America

Subject: **Case M.10442 - ADVENT INTERNATIONAL / SOBI**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

Dear Sir or Madam,

1. On 14 September 2021, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Advent International Corporation ('Advent', USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Swedish Orphan Biovitrum AB ('Sobi', Sweden) by way of public bid announced on 2 September 2021.[3]

2. The business activities of the undertakings concerned are:

   – Advent is a private equity investor based in Boston, USA. Advent focuses on the acquisition of equity stakes and the management of investment funds in various sectors, including healthcare, industrial, technology, retail, consumer and leisure, and business and financial services.

   – Sobi is headquartered in Stockholm, Sweden and is listed on the Nasdaq Stockholm stock exchange. Sobi is an originator pharmaceutical company focussing on the treatment of rare diseases, with its principal areas of focus on treatments in haematology and immunology.

---

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union No C 384, 22.9.2021, p. 4.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.[4]

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

4 OJ C 366, 14.12.2013, p. 5.